Mage, LLC Company Profile

03:58 EDT 25th June 2018 | BioPortfolio

Mage, LLC is a group of entrepreneurial business advisors who focus primarily on providing private and emerging companies with a broad range of business and organizational services. Unlike many other business consulting firms, Mage has the breadth and depth of services to identify and manage problems throughout an organization to help our clients grow. We are committed to strengthening an organization's ability to build long-term value and compete successfully in the marketplace by creating leadership, management and business excellence.Mage is at the forefront of organizational effectiveness and management development for emerging companies. Few consulting firms possess our level of commitment to our clients or our reputation for 'hands-on' creative problem solving and counsel.


145 Rosemary Street
United States of America


Phone: 781-449-8366
Fax: 781-449-8301

News Articles [9 Associated News Articles listed on BioPortfolio]

Adaptimmune Presents MAGE-A4 and MAGE-A10 pre-clinical data at American Association for Cancer Research (AACR) Annual Meeting

- Preclinical testing raises no safety concerns for MAGE A4 -- Refined preclinical testing strategy expected to further mitigate risk of unexpected off-target toxicity - PHILADELPHIA, Pa. and OXF...

MAGE-A-Targeted Immunotherapy Competitor Analysis 2018 –

DUBLIN–(BUSINESS WIRE)–The “Competitor Analysis: MAGE-A-Targeted Immunotherapy” report has been added to’s offering. This Competitive Intelligence ...

2018 Competitor Analysis Report Package: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin –

DUBLIN–(BUSINESS WIRE)–The “Report Package: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin” report has been added to’...

Adaptimmune Presents Detailed Safety Update from Ongoing MAGE-A10 Pilot Studies at ASCO

- Acceptable safety profile with no evidence of off-target toxicity in 100 million cell safety cohorts -  - Dosing continues with the one billion “target” cell dose - PHILADELPHIA, Pa. and OX...

Myxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American Association for Clinical Oncology (ASCO) Annual Meeting

PHILADELPHIA and OXFORD, U.K., May 16, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will release updated data from ongoing clini...

Adaptimmune Announces Positive Safety Data from Pilot Studies with MAGE-A10 SPEAR T-cells and First Patient to Receive 1 billion Target Cell Dose

PHILADELPHIA and OXFORD, United Kingdom, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced initial safety d...

Adaptimmune Announces First Patient to Receive One Billion Target Cell Dose after Positive Safety Data from Pilot Study with MAGE-A4 SPEAR T-cells

- No evidence of off-target toxicity at 100 million cells for second wholly owned asset -              - Synovial sarcoma and MRCLS added to the seven solid tumors already in the MAGE-A4 ba...

Global and North America Popcorn Market Status and Future Forecast 20132023 [Report Updated: 07022018] Prices from USD $2500

SummaryKey Content of Chapters Including and can be customizedPart 1:Market Overview, Development, and Segment by Type, Application RegionPart 2:Global Market by company, Type, Application RegionPar...

Drugs and Medications [0 Results]


PubMed Articles [43 Associated PubMed Articles listed on BioPortfolio]

MAGE-A4 and MAGE-A1 Immunohistochemical Expression in High-grade Endometrial Cancer.

The aim was to investigate MAGE-A4 and MAGE-A1 protein expression in high-grade endometrial cancer and determine its correlation with histologic subtype, FIGO stage, presence of vascular invasion, dis...

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.

Despite newly approved treatments, metastatic melanoma remains a life-threatening condition. We aimed to evaluate the efficacy of the MAGE-A3 immunotherapeutic in patients with stage IIIB or IIIC mela...

Differential long-term medication impact on executive function and delay aversion in ADHD.

The objective was to compare long-term effects of methylphenidate (MPH) and atomoxetine (ATX) on executive functions (EF) and delay aversion (DAv) in ADHD. A randomized controlled trial was conducted....

MAGE-A antigens as targets for cancer immunotherapy.

Targeted anti-cancer therapies aim at reducing side effects while retaining their anti-cancer efficacy. Immunotherapies e.g. monoclonal antibodies, adoptive T cell therapy and cancer vaccines are used...

MAGE in yeast is a go.

Clinical Trials [33 Associated Clinical Trials listed on BioPortfolio]

MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers

This study will investigate the safety and tolerability of MAGE A10ᶜ⁷⁹⁶T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose melanoma or bladder or head ...

A Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers

Participants who are HLA-DPB1*04:01 positive and whose tumors are MAGE-A3/A6 positive may be eligible for this study. If eligible, white blood cells are collected by apheresis and genetica...

The Correlation Between MAGE-A3, PRAME Polymorphism and Expression Levels of MAGE-A3 and PRAME in NSCLC Patients

Considering the low expression rate of Melanoma-associated antigen 3 (MAGE-A3) in Asian especially Southeast Asian, it would be great interests to investigate the potential polymorphism of...

MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine, With Transgenic MAGE-A3 Insertion in Patients With Incurable MAGE-A3-Expressing Solid Tumours

This research is being done because these viruses have been shown to shrink tumours in animals and human tumour samples by selectively killing cancer cells and creating an immune response ...

MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma

This study is being done to evaluate the safety and the clinical activity of MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in patients with unresectable and progressive metastatic cuta...

Companies [4 Associated Companies listed on BioPortfolio]

Mage, LLC

Mage, LLC is a group of entrepreneurial business advisors who focus primarily on providing private and emerging companies with a broad range of business and organizational services. Unlike many other ...

APO-T B.V. and LinXis B.V.

APO-T is a biopharmaceutical company focused on the development and commercialization of proprietary biotherapeutics for oncology. APO-T has developed fully-human antibodies and a...


En effet, l’Auvergne a inversé la tendance démographique qui la voyait perdre 1.300 habitants par an entre 1982 et 1998. Les premiers résultats du recensement INSEE confirment que la région a en...

Adaptimmune Limited

Adaptimmune Limited is focused on the use of T cell therapy to treat HIV and cancer. It aims to utilize the body’s own machinery – the T lymphocyte cell – to target and destroy can...

More Information about "Mage, LLC" on BioPortfolio

We have published hundreds of Mage, LLC news stories on BioPortfolio along with dozens of Mage, LLC Clinical Trials and PubMed Articles about Mage, LLC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Mage, LLC Companies in our database. You can also find out about relevant Mage, LLC Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record